BeOne Medicines (ONC) Proxy filing summary

Executive summary

• Annual General Meeting scheduled for June 11, 2026, in Zürich, Switzerland.

• Shareholders of record as of May 22, 2026, are eligible to vote.

• Proxy materials, including the annual report and proxy card, are available online and by request.

Voting matters and shareholder proposals

• Approval of audited Swiss statutory standalone and consolidated financial statements for fiscal year 2025.

• Approval of appropriation of accumulated loss for fiscal year 2025.

• Discharge of Board and Executive Management Team from liability for the applicable period.

• Election and re-election of directors and Chairman for terms until the 2027 annual meeting.

• Election of Compensation Committee members and Independent Voting Representative.

• Ratification of Ernst & Young entities as independent and statutory auditors for fiscal year 2026.

• Authorization for Board to fix auditors' compensation for fiscal year 2026.

• Advisory approval of executive compensation and Swiss Statutory Compensation Report for fiscal year 2025.

• Approval of maximum aggregate compensation for Board and Executive Management Team under Swiss law.

• Advisory approval of Swiss Statutory Non-Financial Matters Report for fiscal year 2025.

• Approval of amendments to 2016 Share Option and Incentive Plan and 2018 Employee Share Purchase Plan.

• Approval of share issue and repurchase mandates under HK Listing Rules.

• Authorization to allocate shares to Amgen Inc. to maintain its shareholding percentage for five years.

• Approval for adjournment of the meeting if additional proxies are needed.

Board of directors and corporate governance

• Multiple directors nominated for re-election and new directors nominated for election, each for terms until the 2027 annual meeting.

• Chairman and Compensation Committee members to be elected or re-elected for terms until the 2027 annual meeting.

• Independent Voting Representative to be elected for a term until the 2027 annual meeting.